We are live on ! Find out more
TMDX icon

Transmedics

110 hedge funds and large institutions have $561M invested in Transmedics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 38 increasing their positions, 34 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more capital invested

Capital invested by funds: $385M → $561M (+$177M)

43% more call options, than puts

Call options by funds: $824K | Put options by funds: $576K

12% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 34

2.27% more ownership

Funds ownership: 72.31%74.59% (+2.3%)

9% less funds holding

Funds holding: 121110 (-11)

37% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 27

Holders
110
Holders Change
-11
Holders Change %
-9.09%
% of All Funds
1.73%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
17
Increased
38
Reduced
34
Closed
27
Calls
$824K
Puts
$576K
Net Calls
+$248K
Net Calls Change
+$262K

TMDX Hedge Fund Activity: Q1 2022 in Review

110 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Transmedics (TMDX) for Q1 2022, worth a combined $561M — up 46% from $385M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of TMDX and 17 opened new positions — a net loss of 10 holders — while 34 trimmed existing stakes and 38 added.

The largest buyer was Macquarie Group, adding an estimated $7.62M. The largest seller was T. Rowe Price Associates, cutting an estimated $3.19M.

  • 110 institutional investors held Transmedics (TMDX) as of Q1 2022, down from 121 in Q4 2021.
  • Funds reported $561M of Transmedics stock for Q1 2022, up 46% quarter-over-quarter.
  • 17 funds opened new Transmedics positions in Q1 2022 and 27 closed out, a net change of -10 holders.
  • The largest Transmedics buyer in Q1 2022 was Macquarie Group, an estimated $7.62M added.
  • The largest Transmedics seller in Q1 2022 was T. Rowe Price Associates, an estimated $3.19M sold.

Based on aggregated 13F filings for Q1 2022.